Merck and Abide deal to develop diabetes drugs may be worth $430M

05/3/2013 | Genetic Engineering & Biotechnology News

Merck & Co. and Abide Therapeutics will collaborate in the discovery, development and marketing of small molecule drugs for type 2 diabetes and other metabolic conditions. The target will be serine hydrolases, a family of enzymes. The deal entitles Abide to as much as $430 million in an upfront payment, research funding and milestone fees for three products, plus sales royalties. Merck will get the global rights to market any drugs arising from the collaboration.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief: